tafamidis
Sign in to saveAlso known as FX-1006, 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid, tafamidisum
Tafamidis, sold under the brand names Vyndaqel and Vyndamax, is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy, as well as wild-type transthyretin amyloidosis, which formerly was called senile systemic amyloidosis. It works by stabilizing the quaternary structure of the protein transthyretin. In people with transthyretin amyloidosis, transthyretin falls apart and forms clumps called (amyloid) that harm tissues including ne
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458948015
- Drug.image
- Tafamidis.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.tradename
- Vyndaqel, Vyndamax, others
- Drug.DailyMedID
- Tafamidis
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- N07
- Drug.ATC_suffix
- XX08
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Wikidata facts
- Mass
- 306.98
Show 4 more facts
- chemical formula
- C₁₄H₇Cl₂NO₃
- canonical SMILES
- C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
- World Health Organisation international non-proprietary name
- tafamidis
- defined daily dose
- 20
via Wikidata · CC0
~6 min read
Article
11 sectionsContents
- Medical use
- Adverse effects
- Interactions
- Pharmacology
- Chemistry
- History
- Society and culture
- Legal status
- Economics
- References
- Further reading
Tafamidis, sold under the brand names Vyndaqel and Vyndamax, is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy, as well as wild-type transthyretin amyloidosis, which formerly was called senile systemic amyloidosis. It works by stabilizing the quaternary structure of the protein transthyretin. In people with transthyretin amyloidosis, transthyretin falls apart and forms clumps called (amyloid) that harm tissues including nerves and the heart.
The US Food and Drug Administration considers tafamidis to be a first-in-class medication.